Latest research on Leflunomide

Leflunomide is a pyrimidine synthesis inhibitor belonging to the DMARD (disease-modifying antirheumatic drug) class of drugs, which are chemically and pharmacologically very heterogeneous. Leflunomide was approved by FDA and in many other countries (e.g., Canada, Europe) in 1999.

Latest findings

There is an ongoing debate over the efficacy and safety of immunosuppressive agents other than glucocorticoid monotherapy in patients with IgAN who present with moderate to severe proteinuria; specifically, the use of relatively novel agents, including Leflunomide (LET) and Mycophenolate mofetil (MMF). [source, 2016]
Other DMARDs (such as methotrexate and Leflunomide) also have this mechanism of action on macrophage populations; moreover they inhibit cell replication and recruitment of immature and inflammatory monocytes to sites of inflammation. [source, 2016]
This is one of the effects of DMARDs (such as methotrexate and Leflunomide) on macrophage populations, in addition to inhibition of cell replication and recruitment of immature and inflammatory monocytes to sites of inflammation.13 [source, 2016]
Other Disease-Modifying Antirheumatic Drugs (DMARDs) like Leflunomide, Cyclosporine, and Azathioprine were infrequently used and they were not included. [source, 2016]
Unfortunately he developed an empyema, necessitating the cessation of Leflunomide and TCZ. [source, 2016]
Leflunomide was restarted in 2014 and he remains clinically stable on Prednisolone 4 mg. [source, 2016]
Leflunomide and TCZ were introduced resulting in good disease control, and reduced CRP (7). [source, 2016]
Leflunomide was discontinued in 2013 secondary to hypertension and diarrhoea, and methotrexate was started. [source, 2016]
He was unable to reduce the dose below 20 mg and Leflunomide was added. [source, 2016]
His symptoms remain stable on TCZ, Leflunomide and methotrexate. [source, 2016]